Formulary Monographs [BICALUTAMIDE, 1000]
|
|
BICALUTAMIDE
|
|
|
|
|
|
ANTINEOPLASTICS
|
|
|
Bicalutamide is indicated either alone or as adjuvant to radical prostatectomy or radiotherapy in patients with locally advanced prostate cancer at high risk for disease progression.
|
|
|
Consider periodic liver function tests. Constipation, dyspepsia, flatulence, pruritus, asthenia, alopecia, jaundice, dry skin, hot flashes, gynaecomastia and/or breast pain and photosensitivity.
|
|
|
50mg once daily in conjunction with a gonadotropin-releasing hormone (GnRH) analog.
150 mg once a day as monotherapy |
|
|
Bicalutamide is an inhibitor of CYP 3A4, with lesser inhibitory effects on CYP 2C9, 2C19 and 2D6 activity.
Caution should be exercised with the co-administration of bicalutamide with compounds such as ciclosporin and calcium channel blockers. In vitro studies have shown that bicalutamide can displace the coumarin anticoagulant warfarin from its protein binding sites. |
|
|
Bicalutamide is contraindicated in females and should not be used
|
|
|
Bicalutamide is contraindicated in females and should not be used during breast-feeding.
|
|
|
|